Newsletter Signup | Join Community
Stay Current With Multiple Myeloma Treatment Advances & Connect with Others
Empliciti combined with Revlimid or Pomalyst delays progression and prolongs survival in recurrent multiple myeloma.
Dr. Craig Hofmeister, MD guest-moderated on CancerConnect for a question-and-answer session in the Multiple Myeloma
Sarah Holstein, MD, PhD from Roswell Park Cancer Institute answered questions on multiple myeloma: join the conversation
Multiple Myeloma Patients with Medicare can Submit Application for Reimbursement for Thalidomide
CancerConnect Marks Milestone in Multiple Myeloma Community
Gene editing expands reach of therapeutic T cells, in mice
Aplidin® Improves Progression-Free Survival in Multiple Myeloma
Farydak® Significantly Improves Outcomes for Heavily Pre-Treated Multiple Myeloma
Yale Researchers Discover Underlying Cause of Myeloma.
Investigational T-cell Receptor Therapy Achieves Encouraging Clinical Responses in Multiple Myeloma Patients
AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma
SAR 650948 Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma
Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma in Mayo Clinic-Led Study
Leukemia Society Summarizes Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings
Imbruvica® Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma.
Revlimid Linked with Second Primary Malignancies in Patients with Myeloma
Useful resources for individuals with Multiple Myeloma
Management of a Solitary Plasmacytoma
MLN9708 “Oral Velcade” Shows Promise in Multiple Myeloma
Complete Remission Predicts for Long Survival in Multiple Myeloma
Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions
Treatment of Relapsed Myeloma with Second Stem Cell Transplant Appears Safe
Improved Survival with Zometa in Multiple Myeloma
Thalomid® – Prolongs Survival in Multiple Myeloma
Pesticides Linked to Precancerous Blood Disorder
Quantity of Cancer Cells in Bone Marrow Following Stem Cell Transplantation Indicative of Outcome in Multiple Myeloma
Being Overweight Associated with Increased Risk of Several Cancers
Obesity Increases Risk of Multiple Myeloma.
Autologous Transplant Followed by Allogeneic Transplants Superior to Two Autologous Transplants in Multiple Myeloma
Addition of Thalomid® to VAD-Doxil® Improves Outcomes for Multiple Myeloma
Multiple Myeloma Treatment Does Not Affect the Outcome of Stem Cell Transplant
Addition of Velcade® to Standard Therapy Improves Survival in Multiple Myeloma
Further Results Document Effectiveness of Thalidomide and Dexamethasone as Initial Therapy for Multiple Myeloma
Thalomid®/Alkeran®/Prednisone Named New Standard of Care as Initial Treatment for Elderly Patients with Multiple Myeloma
MRI Useful in Detecting Bone Abnormalities in Multiple Myeloma.
Low-dose Steroids Improve Survival in Multiple Myeloma
Velcade®, Alkeran®, Prednisone, and Thalomid® Effecive for Relapsed Multiple Myeloma
Doxil® Associated with Fewer Heart Side Effects than Adriamycin® in Multiple Myeloma
Doxil®, Oncovin®, Revlimid®, and Dexamethasone Effective in Recurrent Multiple Myeloma
Mini Allogeneic Transplant Not Superior to Autologous Stem Cell Transplant
Addition of Thalidomide to Melphalan Appears Promising for Elderly Patients with Newly Diagnosed Multiple Myeloma
Thalidomide Not Associated with Survival Improvement in Multiple Myeloma
Firefighters Face Increased Risk of Cancer
Osteonecrosis refers to the death of bone.
Velcade® plus Melphalan Shows Encouraging Activity in Multiple Myeloma
Thalomid® Approved for Treatment of Newly Diagnosed Multiple Myeloma
Comparison of High-Dose to Standard-Dose Therapy in Multiple Myeloma
Thalidomide Beneficial in Multiple Myeloma Patients Ineligible for Stem Cell Transplants
Thalomid®, Doxil®, and Dexamethasone Effective in Elderly with Myeloma
Addition of Thalomid® to Dexamethasone Improves Progression-Free Survival in Multiple Myeloma
Genasense®/Thalomid®/Dexamethasone Promising for Recurrent Multiple Myeloma
MRI of Bone Marrow Predicts Outcomes of Multiple Myeloma
Velcade® Overcomes Poor Prognosis of Genetic Mutation in Multiple Myeloma
Treanda™/Prednisone Superior to Melphalan/Prednisone for Multiple Myeloma
Combination of Drugs Shows Promise for Treatment of Multiple Myeloma
Combination Autologous/Allogeneic Transplant More Effective than Double Autologous Transplants in Multiple Myeloma.
Initial Treatment with Thalidomide Superior to Chemotherapy VAD for Multiple Myeloma
Immunization May Guide Future of Bone Marrow Transplants for Multiple Myeloma
Multiple Myeloma Survival Linked with Circulating Plasma Cells
Distinct Subgroup of Multiple Myeloma Patients
Circulating Cancer Cells Indicate Worse Outcomes Following Autologous Stem Cell Transplantation in Multiple Myeloma
Addition of Thalidomide to Dexamethasone Improves Responses in Multiple Myeloma
High-Dose Chemotherapy Improves Survival as Initial Therapy in Multiple Myeloma
Holmium 166 a Promising Component of High-Dose Therapy in Multiple Myeloma.
Gene Identified that Promotes Bone Lesions in Multiple Myeloma
Two Autologous Stem Cell Transplants Improve Survival Over Single Transplant in Multiple Myeloma
Velcade® Safe and Effective for Patients with Multiple Myeloma and Kidney Failure
Double Autologous Stem Cell Transplant Significantly Improves Survival in Some Patients with Multiple Myeloma
Melphalan/Prednisone Favorable in Multiple Myeloma Patients Ineligible for High-Dose Therapy
DVd-T Results in High Anti-Cancer Response Rates in Multiple Myeloma.
Additional Evidence Shows Thalomid® Improves Survival in Elderly with Multiple Myeloma
Chronic Graft-Versus-Host-Disease Improves Survival of Multiple Myeloma Patients Receiving Stem Cell Transplants
Genasense™ may Reverse Chemotherapy Resistance in Multiple Myeloma
Thalidomide Derivative CC-5013 Produces Responses in Refractory Multiple Myeloma.
Pivotal Trial Evaluating New Holmium Treatment for Myeloma is Launched
Multiple Myeloma Patients who do Not Respond to Induction Therapy Benefit from Autologous Stem Cell Transplant
Renal Failure Should Not Exclude Multiple Myeloma Patients from Receiving Autologous Stem Cell Transplants.
Sequential Stem Cell Transplants Promising for Relapsed Multiple Myeloma
Thalidomide May Increase Risk for Deep Vein Thrombosis in Multiple Myeloma Patients
Medicare Now Required to Pick Up Costs for High-Dose Chemotherapy Treatment of Patients with Multiple Myeloma
Test Identifying Cell Genetic Abnormalities Can Help Predict Survival after Standard-Dose Chemotherapy for Persons
Thalidomide Derivatives Show Promise in the Treatment of Multiple Myeloma
Patients with Asymptomatic Multiple Myeloma May Not Benefit from Early Treatment
Donor Lymphocyte Infusions May Prolong Survival in Persons with Multiple Myeloma Recurring After Allo-SCT
Patients with Solitary Plasmacytoma May Not Benefit from Initial Chemotherapy Treatment
Nordic Myeloma Study Group Concludes High-Dose Therapy Improves Survival of Patients with Multiple Myeloma
New Biologic Therapy, Using Dendritic Cells, Produces Responses in Persons with Low-Burden Multiple Myeloma
The Cytogenetic Abnormality, 13q14, is Present in Half of All Patients with Multiple Myeloma
Stem Cell Transplantation for Multiple Myeloma: CD34-Selection Does Not Prolong Survival
Studies Suggest Thalidomide for Multiple Myeloma
Older Patients with Multiple Myeloma Benefit from Treatment with Stem Cell Transplant
Novel Therapy for Recurrent Multiple Myeloma
The severity of anemia and the need for blood transfusions can be markedly reduced in patients with multiple myeloma
Bone Seeking Isotope, Homium, May Improve Results of Autologous Transplants for Mutlitple Myeloma.
Tandem Autologous Transplants More Effective than Single Autologous Transplants for Patients with Multiple Myeloma
Dendritic Cell Vaccination in Patients with Multiple Myeloma Produces Immune and Therapeutic Responses
Cancer cells require food, oxygen, and growth proteins in order to grow and spread.
A New Option for High-risk Multiple Myeloma?
Hepatitis C Infection Increases Risk of Lymphoma and Multiple Myeloma
New technology, not yet tested in humans, aims to reduce patients’ waiting time, increase potency of T-cell therapy
Allo: Multiple MyelomaOverview
Low-Dose Radiation plus Donor Lymphocyte Infusion Produces Responses in Refractory Hematologic Cancers
Preventive Dental Care Reduces Osteonecrosis of the Jaw Associated with Bisphosphonates
Managing Complications & Side Effects of Myeloma
Has anyone elected to receive triple drug therapy and delay their ASCT? Seems like there is…
New Antibody that targets CD74 on myeloma cells gets nod from FDA to proceed. …
UK doctors identify a new target for treating Multiple Myeloma: …